In addition, a very recent study reported that AChE inhibitor treatments are associated with lower mortality in patients with diabetes mellitus with Alzheimer's disease or patients with mixed-pathology dementia, with a specific benefit provided by galantamine or another AChE inhibitor—donepezil (67). This evidence concerns the gene ACHE and early-onset autosomal dominant Alzheimer disease.